PATENT CLAIM ANALYSIS

Application Number: 16014255
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["424", "133100"]

Abstract:
The present disclosure relates to a novel class of anti-HER2 monoclonal antibodies comprising a homogeneous population of anti-HER2 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-HER2 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.

Claim (Index 29):
The method of  claim 19 , wherein the \u03b1-fucosidase is a recombinant  Bacteroides  \u03b1-fucosidase.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 94.0
- Lexical Diversity: 1.5
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14723181', '15011544', '16011622', '14203479', '13811045']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6273906241006274
- 35 USC 102 Novelty (BERT): 0.5894673056422284
- Combined Prediction Score: 0.6235982922547875
- Mean Citation Score: 400.805346
- Max Citation Score: 624.2132
- Similarity Product: 366.9509317502976

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test